颈动脉干预中双联与单联抗血小板治疗的系统综述与荟萃分析
该研究系统检索随机对照试验和观察性研究,比较颈动脉内膜剥脱术和颈动脉支架置入术中双联与单联抗血小板治疗的效果。共纳入3项随机对照试验和7项观察性研究,涉及36,881例颈动脉内膜剥脱术和150例颈动脉支架置入术。结果显示,双联抗血小板治疗仅在颈动脉支架置入术中减少短暂性脑缺血发作方面有优势,但在颈动脉内膜剥脱术中增加出血并发症风险。
要点
- 颈动脉内膜剥脱术中,双联抗血小板治疗不改善卒中/短暂性脑缺血发作/死亡,但增加大出血和颈部血肿风险。
核心结论
- 双联抗血小板治疗仅在颈动脉支架置入术中显示优势,表现为短暂性脑缺血发作风险降低。
- 颈动脉内膜剥脱术患者接受双联抗血小板治疗与出血并发症风险增加相关。
研究设计与样本
- 系统综述与荟萃分析,检索MEDLINE、EMBASE、CINAHL、CENTRAL及参考文献列表。
- 纳入报告颈动脉内膜剥脱术和颈动脉支架置入术中双联与单联抗血小板治疗比较结局的随机对照试验和观察性研究。
- 共纳入3项随机对照试验和7项观察性研究,涉及36,881例颈动脉内膜剥脱术和150例颈动脉支架置入术。
主要发现
- 颈动脉内膜剥脱术中,单联与双联抗血小板治疗在卒中/短暂性脑缺血发作/死亡方面无差异。
- 颈动脉支架置入术中,双联与单联治疗在大出血或血肿形成方面无差异。
关键数值与推荐
- 颈动脉内膜剥脱术:双联抗血小板治疗不改善卒中/短暂性脑缺血发作/死亡,但增加大出血、颈部血肿和心肌梗死风险。
临床怎么用
- 颈动脉支架置入术患者可考虑双联抗血小板治疗以降低短暂性脑缺血发作风险。
- 颈动脉内膜剥脱术患者采用双联抗血小板治疗需权衡出血并发症风险。
局限性
- 纳入研究包括观察性研究,可能存在偏倚。
- 颈动脉支架置入术样本量较小(150例),结果需谨慎解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The importance of antiplatelet therapy for the management and prevention of ischaemic stroke cannot be overstated. Despite the established guidelines, there is no clear consensus on how to manage antiplatelet therapy during and after carotid interventions. OBJECTIVE: The objective was to undertake a systematic literature review and perform a meta-analysis to assess the effects of dual antiplatelet therapy in carotid endarterectomy (CEA) and stenting (CAS). DATA SOURCES: Electronic information sources (MEDLINE, EMBASE, CINAHL, CENTRAL) and bibliographic reference lists were searched to identify randomised controlled trials (RCTs) and observational studies reporting comparative outcomes of dual versus single antiplatelet therapy in CEA and CAS. METHODS: Primary outcomes were mortality and stroke within 30 days of intervention. Secondary outcomes were transient ischaemic attack (TIA), major bleeding, groin or neck haematoma, and myocardial infarction (MI). Dichotomous outcome measures were reported using the risk difference (RD) and 95% confidence interval (CI). Combined overall treatment effects were calculated using fixed-effect or random-effects models. RESULTS: Three RCTs and seven observational studies were identified reporting a total of 36,881 CEAs and 150 CAS procedures. In CEA, there were no differences in stroke/TIA/death between single and dual antiplatelet therapy, but there was a significant risk of major bleeding (RD, 0.00; 95% CI, 0.00-0.01; p = .0003) and neck haematoma with dual therapy (RD, 0.04; 95% CI, 0.01-0.06; p = .001). In addition, the rate of MI was higher in the dual therapy group than the single therapy group (RD, 0.00; 95% CI, 0.00-0.01; p = .003). In CAS, there was no difference in major bleeding or haematoma formation, but a significant difference in TIA in favour of dual therapy was identified (RD -0.13, 95% CI, -0.22 to -0.05; p = .003). CONCLUSIONS: Dual antiplatelet therapy demonstrates advantages over single therapy only in CAS, as indicated by a reduced risk of TIA. Dual antiplatelet therapy was associated with an increased risk of bleeding complications in patients undergoing CEA.
引用
- Barkat M, Hajibandeh S, Hajibandeh S, et al. Systematic Review and Meta-analysis of Dual Versus Single Antiplatelet Therapy in Carotid Interventions. Eur J Vasc Endovasc Surg. 2016. PMID: 27894896. doi:10.1016/j.ejvs.2016.10.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。